Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the Mouse
Purpose Acute myocardial infarction (AMI) drives an intense inflammatory response that contributes to infarct healing and cardiac remodeling. Recently, different studies have identified a role of interleukin-1 (IL-1) in the development of adverse cardiac remodeling. However, in animal models of AMI IL-1 has been shown to be cardioprotective in preconditioning, raising the question of clinical safety of therapeutic IL-1 blockade for autoinflammatory diseases or for the prevention or the treatment of AMI. In this study we proposed to evaluate the effects of pretreatment with recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) on ischemia reperfusion (I/R) injury to the heart. Methods RhIL-1Ra was given 4 h or 30 min before the surgical induction of I/R. Left ventricular ejection fraction(LVEF) and infarct size were assessed to determine the effects of the drug pretreatment compared to vehicle treated mice. Results RhIL-1Ra, given 4 h or 30 min before the onset of the ischemia, showed marked cardioprotection though preservation of the LVEF (no change vs sham operated mice) and the reduction of the infarct size (−40 % vs vehicle-treated mice). No differences were observed between the two groups of rhIL-1Ra treatment. Conclusions IL-1 blockade therapies using rhIL-1Ra prior the onset of AMI protects the myocardium and preserves cardiac function..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2012 |
---|---|
Erschienen: |
2012 |
Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
---|---|
Enthalten in: |
Cardiovascular drugs and therapy - 26(2012), 3 vom: 13. Apr., Seite 273-276 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Toldo, Stefano [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: |
---|
Anmerkungen: |
© Springer Science+Business Media, LLC 2012 |
---|
doi: |
10.1007/s10557-012-6389-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2042910732 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2042910732 | ||
003 | DE-627 | ||
005 | 20230518172550.0 | ||
007 | tu | ||
008 | 200819s2012 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s10557-012-6389-x |2 doi | |
035 | |a (DE-627)OLC2042910732 | ||
035 | |a (DE-He213)s10557-012-6389-x-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 15,3 |2 ssgn | ||
084 | |a PHARM |q DE-84 |2 fid | ||
084 | |a 44.40 |2 bkl | ||
100 | 1 | |a Toldo, Stefano |e verfasserin |4 aut | |
245 | 1 | 0 | |a Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the Mouse |
264 | 1 | |c 2012 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Springer Science+Business Media, LLC 2012 | ||
520 | |a Purpose Acute myocardial infarction (AMI) drives an intense inflammatory response that contributes to infarct healing and cardiac remodeling. Recently, different studies have identified a role of interleukin-1 (IL-1) in the development of adverse cardiac remodeling. However, in animal models of AMI IL-1 has been shown to be cardioprotective in preconditioning, raising the question of clinical safety of therapeutic IL-1 blockade for autoinflammatory diseases or for the prevention or the treatment of AMI. In this study we proposed to evaluate the effects of pretreatment with recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) on ischemia reperfusion (I/R) injury to the heart. Methods RhIL-1Ra was given 4 h or 30 min before the surgical induction of I/R. Left ventricular ejection fraction(LVEF) and infarct size were assessed to determine the effects of the drug pretreatment compared to vehicle treated mice. Results RhIL-1Ra, given 4 h or 30 min before the onset of the ischemia, showed marked cardioprotection though preservation of the LVEF (no change vs sham operated mice) and the reduction of the infarct size (−40 % vs vehicle-treated mice). No differences were observed between the two groups of rhIL-1Ra treatment. Conclusions IL-1 blockade therapies using rhIL-1Ra prior the onset of AMI protects the myocardium and preserves cardiac function. | ||
700 | 1 | |a Schatz, Aaron M. |4 aut | |
700 | 1 | |a Mezzaroma, Eleonora |4 aut | |
700 | 1 | |a Chawla, Raveen |4 aut | |
700 | 1 | |a Stallard, Thomas W. |4 aut | |
700 | 1 | |a Stallard, William C. |4 aut | |
700 | 1 | |a Jahangiri, Arehzo |4 aut | |
700 | 1 | |a Van Tassell, Benjamin W. |4 aut | |
700 | 1 | |a Abbate, Antonio |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cardiovascular drugs and therapy |d Springer US, 1987 |g 26(2012), 3 vom: 13. Apr., Seite 273-276 |w (DE-627)130433330 |w (DE-600)639068-7 |w (DE-576)018665950 |x 0920-3206 |7 nnns |
773 | 1 | 8 | |g volume:26 |g year:2012 |g number:3 |g day:13 |g month:04 |g pages:273-276 |
856 | 4 | 1 | |u https://doi.org/10.1007/s10557-012-6389-x |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4219 | ||
912 | |a GBV_ILN_4305 | ||
936 | b | k | |a 44.40 |q VZ |
951 | |a AR | ||
952 | |d 26 |j 2012 |e 3 |b 13 |c 04 |h 273-276 |